跳至主要内容
临床试验/NCT05554445
NCT05554445招募中不适用

Observational Investigation of the CDED in a Real World IBD Clinic: Dietician and Patient Adaptations to the Dietary Protocol

Eli Sprecher, MD2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
2
主要终点
Clinical remission rates will be measured by Harvey-Bradshaw Index at the end of phase 1

研究概览

简要总结

A prospective observational study, which will follow a cohort of adult CD patients who are prescribed the Crohn disease exclusion diet (CDED) during their routine clinical dietary therapy. The diet is composed of three phases, at the end of the first two phases we will evaluate whether the patient achieved remission and at the end of phase three the maintenance of remission. We intend to study achievement and remission rate in association to the diet adaptations made by dieticians at phase 1 and 2, together with patient's choice off food at the third phase under real world clinical setting and patient lifestyle characteristics.

详细描述

This is a prospective observational study that will follow a cohort of CD patients who are prescribed the Crohn disease exclusion diet (CDED) during their routine clinical dietary therapy at the IBD clinic of the TLVMC. The CD exclusion diet (CDED), is a whole-food diet designed to reduce exposure to dietary components, hypothesized to negatively affect the microbiome (dysbiosis), intestinal barrier, and intestinal immunity. We intend to follow patients with proven clinically active disease from the previous 4 months. Disease activity will be determined by Harvey-Bradshaw index (4<HBI<16) and Calprotectin>50g.

The diet is composed of three phases, the first two included 5 mandatory foods consumed daily to provide specific fibers and starches as substrates for short chain fatty acids-producing taxa from Firmicutes, as well as sources of lean protein that were low in animal fat to decrease Proteobacteria and improve intestinal permeability, while maintaining a balanced diet. The diet included avoidance or reduction of exposure to foods containing animal/dairy fat, high fat from other sources, wheat, red or processed meat and protein sources rich in taurine, emulsifiers, artificial sweeteners, carrageenans and sulfites. The second phase stepdown diet involves higher exposure to fruits, vegetables, and legumes along with some foods that are reintroduced with restrictions to increase food flexibility and relieve monotony. The third phase of the study, is considered a maintenance phase in which patients are advised to continue practicing the concepts of the previous two phases, but they may generally manage their diet freely.

In this observational study, we aim to describe our real-world experience with the CDED, in a tertiary referral center for IBD patients. We aim to characterize both the adaptations of the first two phases of the diet practiced by IBD dieticians, and the food choices made by patients during the third phase of the diet . We aim to associate both these determinants with clinical remission at the end of phase two and remission maintenance at the end of phase three respectively.

Data collection

Upon visits, patients will be asked to fill in food frequency questionnaire (FFQ), 3-days recall questionnaires, food related quality of life, CD symptom and pain questionnaire. Dieticians will be asked to meticulously describe the adaptations they have performed in the CDED and the reasons for them at baseline, week 6 and 12. The adaptation will be made in accordance to patient's symptoms and disease characteristics.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Clinically stable CD patients, constant medicinal regimen throughout the study period. Refractory to mesalamine at least 6 weeks, or steroids at least 2 week, or immunomodulator at least 12 weeks or biologics at least 12 weeks therapy, medical cannabis at least 2 weeks before the study.
  • Clinically active disease by CD symptoms score 4 <Harvey-Bradshaw index (HBI) at baseline and Calprotectin>50g/l / endoscopy / imaging proven active disease from the previous 4 months.

排除标准

  • Inability to sign informed consent and complete study protocol

结局指标

主要结局

Clinical remission rates will be measured by Harvey-Bradshaw Index at the end of phase 1

时间窗: week 6, end of phase 1

Achievement of clinical remission by the end of the first phase of the diet, will be defined as HBI(Harvey-Bradshaw Index)\<4

Clinical remission rates will be measured by Harvey-Bradshaw Index at the end of phase 2

时间窗: week 12, end of phase 2

Achievement of clinical remission by the end of the second phase of the diet will be defined as HBI(Harvey-Bradshaw Index)\<4

Rate of patients maintaining clinical remission at the end of phase 3

时间窗: week 24, end of phase 3

Maintaining clinical remission by the end of the third phase of the diet will be defined as HBI(Harvey-Bradshaw Index)\<4

次要结局

  • Associations between food choices during the third phase of the diet made by patients and remission maintenance(week 24)
  • Associations between adaptations of the second phase of the diet practiced by IBD dieticians and clinical remission(week 12)
  • Associations between adaptations of the first phase of the diet practiced by IBD dieticians and clinical remission(week 6)

研究者

发起方
Eli Sprecher, MD
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Eli Sprecher, MD

Head of R&D

Tel-Aviv Sourasky Medical Center

研究点 (2)

Loading locations...

相似试验